Avicanna (TSE:AVCN) has released an update.
Don't Miss Our Christmas Offers:
- Discover the latest stocks recommended by top Wall Street analysts, all in one place with Analyst Top Stocks
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Avicanna Inc., a biopharmaceutical company specializing in cannabinoid-based products, has announced significant growth with Q2 2024 revenues soaring to $6.1 million, marking an 85% increase from the previous year. The company also reported the successful completion of two real-world evidence trials for treatments targeting Epidermolysis Bullosa and musculoskeletal pain, reflecting a strong emphasis on research and development in the medical cannabis field.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.
